Stuart Therapeutics

Stuart Therapeutics is a private, clinical-stage biotech pioneering a novel approach to treating chronic ocular diseases by targeting helical collagen in the extracellular matrix. Its proprietary PolyCol platform technology consists of synthetic peptides designed to bind and repair damaged collagen, a previously 'undruggable' target involved in inflammation and tissue structure. The company's most advanced asset, ST-100 (Vezocolmitide), has reported Phase III results for Dry Eye Disease, and it has secured a key partnership with Glaukos Corporation. With a pipeline focused on major unmet needs in ophthalmology, Stuart aims to develop disease-modifying therapies that go beyond symptom management.

PolyCol platform of synthetic collagen mimetic peptides (CMPs) designed to bind to and repair disease-damaged helical collagen in the extracellular matrix and membranes.

Stuart operates in the highly competitive ophthalmology sector, competing with large pharmaceutical companies and specialized biotechs across its target indications. Its differentiation lies in its first-in-class approach targeting collagen repair, whereas most competitors focus on anti-inflammatory or other symptomatic pathways.